HC may take up Epharmacy ban

CHENNAI: Epharmacies have moved a division bench of the Madras High Court challenging a recent order banning sale of medicines online till the central health ministry formalises the regulatory environment for web-based drug aggregators.

Madras High Court judge Pushpa Sathyanarayana, on Monday, had imposed a restraint on online pharmacies from conducting their businesses and directed the Central Drugs Standard Control Organisation to notify necessary amendments on the Gazette before end of January next year. Against this order, online drug aggregators have litigated before a division bench of the Madras High Court.

“The court is expected to take up the matter on Thursday,” Chandra Kumar, counsellor for the Tamil Nadu Chemists and Druggists Organisation, said.

The TNCDA had won the ban on online sales on grounds that the businesses were operating without valid licences.

While imposing the ban, Madras High Court had faulted the central government for not putting out the final contours of the regulatory environment even after two years since a similar petition was filed with the Madras High Court.

Justice Sathyanarayana, in her order banning sales till January, said: “The central government had already been given a longer rope by the order of the division bench…” adding that the “rules are still at the draft stage” even though its has been two years since the judgement.

Netmeds, one of the respondents to the case, had argued that it was not “violating any law,” particularly ones concerning retail licensing and others. Practo had submitted that a “request for prescription drugs would be rejected, unless a valid prescription is uploaded with such request.”

  • Related Posts

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid